GlassScriptPhysician profile
James X Xu
NPI 1104003342
$9,576.16
in general payments reported to CMS, 2019-2025
68 companies · $2,499 in 2025
The $2,499 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2020: $172 · 2021: $673 · 2022: $1,550 · 2023: $2,086 · 2024: $2,098 · 2025: $2,499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,666 · Education: $17.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,665.59 |
| Education | $17.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,168.17 | 2019-2025 | Kisqali, Piqray |
| Janssen Biotech, INC. | $638.59 | 2019-2025 | Erleada, Darzalex, Talvey |
| Pfizer INC. | $558.33 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $481.00 | 2019-2025 | Imfinzi, Lynparza, Calquence |
| Boston Scientific Corporation | $385.21 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $343.39 | 2023-2025 | Keytruda, Welireg, Keytruda Qlex |
| Daiichi Sankyo INC. | $274.53 | 2021-2025 | Datroway, Enhertu, Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $260.85 | 2022-2025 | Fruzaqla, Ninlaro, Alunbrig |
| E.R. Squibb & Sons, L.L.C. | $247.87 | 2021-2025 | Opdivo, Krazati |
| Janssen Pharmaceuticals, INC | $238.25 | 2021-2024 | Xarelto |
| Incyte Corporation | $228.79 | 2019-2025 | Jakafi, Monjuvi |
| Bayer Healthcare Pharmaceuticals INC. | $216.02 | 2019-2025 | |
| Eisai INC. | $212.86 | 2019-2025 | |
| Array Biopharma INC | $200.73 | 2021-2025 | Braftovi, Lorbrena, Mektovi |
| Abbvie INC. | $192.12 | 2024-2025 |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $184.80 | 2019-2023 | Imbruvica |
| Seagen INC. | $178.66 | 2019-2023 | Tivdak, Adcetris, Tukysa |
| Deciphera Pharmaceuticals INC. | $170.66 | 2022-2025 | Qinlock, Tgct, Romvimza |
| Coherus Oncology, INC. | $163.80 | 2022-2024 | |
| Pharmacosmos Therapeutics INC. | $161.53 | 2022-2025 | Monoferric |
| Genzyme Corporation | $146.29 | 2023-2025 | |
| Amgen INC. | $136.48 | 2022-2023 | Lumakras, Nplate, Xgeva |
| Amneal Pharmaceuticals LLC | $133.21 | 2023-2025 | Alymsys, Avastin |
| Astellas Pharma US INC | $130.54 | 2019-2024 | Padcev, Vyloy |
| Taiho Oncology, INC. | $112.86 | 2022-2024 | |
| Sobi, INC | $107.94 | 2022-2025 | |
| Fresenius Kabi USA, LLC | $107.34 | 2023-2025 | Stimufend |
| Celltrion USA INC. | $102.06 | 2024-2025 | Vegzelma |
| Sun Pharmaceutical Industries INC. | $100.67 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $100.00 | 2025 | Neffy |
| Alnylam Pharmaceuticals INC. | $99.70 | 2022-2025 | Givlaari |
| Emd Serono, INC. | $97.23 | 2019-2024 | |
| Pharmaessentia USA Corporation | $94.52 | 2023-2024 | Besremi |
| Beone Medicines USA, INC. | $93.39 | 2025 | Tevimbra, Brukinsa |
| Genentech USA, INC. | $90.31 | 2019-2023 | Polivy, Lunsumio |
| Tersera Therapeutics LLC | $88.62 | 2022 | |
| Global Blood Therapeutics, INC. | $84.47 | 2022 | |
| Azurity Pharmaceuticals, INC. | $82.29 | 2024-2025 | Danziten, Vivimusta |
| Lilly USA, LLC | $79.11 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Exelixis INC. | $77.24 | 2021-2025 | Cabometyx |
| Glaxosmithkline, LLC. | $76.91 | 2023-2025 | Zejula, Jemperli, Ojjaara |
| Servier Pharmaceuticals LLC | $63.30 | 2022-2025 | |
| Kite Pharma, INC. | $59.77 | 2023-2025 | Yescarta |
| Mirati Therapeutics, INC. | $59.76 | 2023 | Krazati |
| Stemline Therapeutics INC. | $59.00 | 2023-2024 | Orserdu |
| Puma Biotechnology, INC. | $56.92 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $52.24 | 2023-2025 | Ultomiris |
| Recordati_rare_diseases_inc. | $44.69 | 2023-2025 | Sylvant |
| Beigene USA, INC. | $44.31 | 2024-2025 | Tevimbra |
| Organon LLC | $39.98 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.68 | 2023-2024 | |
| Caris Mpi, INC. | $38.39 | 2025 | Mi Cancer Seek |
| Kyowa Kirin, INC. | $37.93 | 2022-2025 | |
| Agios Pharmaceuticals, INC. | $36.66 | 2024 | Pyrukynd |
| Novocure INC. | $36.62 | 2024 | Optune Lua (Novottf-200t) |
| Cti Biopharma Corp. | $36.50 | 2023 | Vonjo |
| Heron Therapeutics, INC. | $32.14 | 2019-2020 | |
| Celgene Corporation | $23.87 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $22.45 | 2022 | |
| Myriad Genetic Laboratories, INC. | $19.71 | 2025 | Myrisk |
| Gilead Sciences, INC. | $18.54 | 2023 | |
| Morphosys, US INC. | $18.50 | 2021 | |
| Spectrum Pharmaceuticals INC. | $16.81 | 2023 | Rolvedon |
| Karyopharm Therapeutics INC. | $16.13 | 2020 | |
| Eusa Pharma (US) LLC | $15.14 | 2022 | |
| Foundation Medicine, INC. | $14.49 | 2023 | |
| Equashield LLC | $13.17 | 2025 | Equashield |
| Tactile Systems Technology INC | $13.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Xu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.